Walleye Capital
CRSP icon

Walleye Capital’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
24,136
+23,221
+2,538% +$1.22M ﹤0.01% 1886
2026
Q1 		$43.5K Buy
+915
New +$48.3K ﹤0.01% 3935
2025
Q3 		– Sell
-25,131
Closed -$1.44M – 4608
2025
Q2 		$1.22M Sell
25,131
-133,304
-84% -$5.16M ﹤0.01% 1890
2025
Q1 		$5.39M Buy
158,435
+142,908
+920% +$6.06M 0.02% 734
2024
Q4 		$611K Buy
15,527
+15,122
+3,734% +$714K ﹤0.01% 2828
2024
Q3 		$19K Sell
405
-331
-45% -$16.8K ﹤0.01% 4822
2024
Q2 		$39.8K Buy
736
+144
+24% +$8.33K ﹤0.01% 4989
2024
Q1 		$40.4K Buy
+592
New +$42.4K ﹤0.01% 4749
2023
Q1 		– Sell
-32,358
Closed -$1.57M – 3992
2022
Q4 		$1.32M Buy
+32,358
New +$1.72M 0.02% 819
2019
Q4 		– Sell
-1,555
Closed -$64K – 1874
2019
Q3 		$64K Buy
+1,555
New +$74.3K ﹤0.01% 1544

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's CRSP Position: Q2 2026 in Review

Walleye Capital increased its CRISPR Therapeutics (CRSP) stake by 2,538% in Q2 2026, buying an estimated $1.22M and bringing the position to 24,136 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1886.

Walleye Capital first reported a position in CRSP in Q3 2019 and has held it in 10 quarters since. The position peaked at $5.39M in Q1 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Walleye Capital held 24,136 shares of CRISPR Therapeutics worth $1.32M as of Q2 2026.
  • Walleye Capital bought 23,221 CRISPR Therapeutics shares in Q2 2026, an estimated $1.22M.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #1886 holding.
  • Walleye Capital first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 10 quarters since.
  • Walleye Capital's CRISPR Therapeutics position peaked at $5.39M in Q1 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.